#AnthemBiosciencesIPO #IPOAlert #NewListing #PharmaIPO #StockMarketIndia #InvestSmart #SEBI #BookBuilding #AnchorInvestors #RetailInvestors #IPOSeason
Chandigarh: Anthem Biosciences Limited, a leading player in the contract research and manufacturing services (CRAMS) sector, is set to open its much-anticipated Initial Public Offering (IPO) on Monday, July 14, 2025. The IPO will remain open for three days and close on Wednesday, July 16, 2025.
The price band for the offer has been fixed at ₹540 to ₹570 per equity share with a face value of ₹2 each. Interested investors can bid for a minimum of 26 equity shares and in multiples of 26 shares thereafter. The company has also announced an Anchor Investor bidding date on Friday, July 11, 2025, one working day before the public opening.
The IPO will be conducted via the Book Building Process, in accordance with the SEBI (ICDR) Regulations, and the company’s equity shares are proposed to be listed on both the BSE and NSE stock exchanges.
💼 Offer Structure and Breakdown
The total issue comprises an Offer for Sale (OFS) of equity shares aggregating up to ₹33,950 million by existing shareholders. This includes:
-
₹3,500 million worth of shares by Ganesh Sambasivam
-
₹3,500 million by K. Ravindra Chandrappa
-
₹13,250 million by Viridity Tone LLP
-
₹3,200 million each by Portsmouth Technologies LLC, Malay J. Barua, Rupesh N. Kinekar, and Satish Sharma
-
₹800 million by Prakash Kariabettan
-
₹100 million by K. Ramakrishnan
The offer also includes a special reservation for eligible employees, with equity shares worth ₹82.50 million earmarked under the Employee Reservation Portion. A discount of ₹50 per equity share will be offered to employees participating in this category.
📊 Investor Allocation Details
The IPO allocation will be made as per the SEBI regulations:
-
Up to 50% of the offer will be allocated to Qualified Institutional Buyers (QIBs), including up to 60% reserved for Anchor Investors, of which one-third is set aside for domestic mutual funds.
-
15% of the offer will be allocated to Non-Institutional Investors (NIIs), split further:
-
One-third for bids of ₹2 lakh to ₹10 lakh
-
Two-thirds for bids above ₹10 lakh
-
-
35% of the offer will be reserved for Retail Individual Investors (RIIs)
-
A proportionate allocation will also be made for eligible employees applying under the reserved category.
If any category sees under-subscription, the remaining shares may be reallocated to other eligible categories in line with regulatory provisions.
🏦 Application and ASBA Process
All investors—except Anchor Investors—must participate through the Application Supported by Blocked Amount (ASBA) process. Applicants must provide details of their bank accounts or UPI IDs to block the bid amount.
Anchor Investors will not be permitted to apply through ASBA. The Self-Certified Syndicate Banks (SCSBs) will block the bid amounts in the respective accounts until final allotment.
🔍 Red Herring Prospectus and Key Advisors
The company’s Red Herring Prospectus (RHP), dated July 8, 2025, can be accessed via this link.
The IPO is being managed by an experienced consortium of Book Running Lead Managers (BRLMs), including:
-
JM Financial Limited
-
Citigroup Global Markets India Private Limited
-
J.P. Morgan India Private Limited
-
Nomura Financial Advisory and Securities (India) Private Limited
🌐 Company Overview
Anthem Biosciences is a fast-growing contract research and manufacturing company, specializing in biopharmaceutical development, chemical synthesis, analytical services, and large-scale manufacturing. Its IPO is seen as a major event in the Indian healthcare and biotech space, especially given growing investor appetite for innovation-led enterprises in these sectors.
📈 Market Expectations and Listing
Market analysts are watching this IPO closely, citing strong sector tailwinds and increasing demand for CDMO/CRAMS services from global pharmaceutical giants. The listing is expected to draw attention from both institutional and retail investors due to the company’s robust fundamentals and strategic global partnerships.
Post allotment, the equity shares will be listed on the BSE and NSE, offering liquidity and broader market participation.
📌 Important Dates
-
Anchor Bidding Date: July 11, 2025 (Friday)
-
IPO Opens: July 14, 2025 (Monday)
-
IPO Closes: July 16, 2025 (Wednesday)
-
Price Band: ₹540 – ₹570
-
Lot Size: 26 shares and multiples thereafter
-
Listing: BSE & NSE
📣 Investor Advisory
Investors are advised to read all offer documents carefully, including the RHP, before subscribing. Participation in the IPO should be aligned with investment goals, financial standing, and risk appetite.
🔖 Hashtags
#AnthemBiosciencesIPO #IPOAlert #NewListing #PharmaIPO #StockMarketIndia #InvestSmart #SEBI #BookBuilding #AnchorInvestors #RetailInvestors #IPOSeason #UpcomingIPO #EmployeeReservation #BiotechIndia #HealthcareIPO #AnthemBiosciences #EquityMarkets #MutualFunds #BSE #NSE #FinancialNews #ChandigarhUpdates #InitialPublicOffering
